NeuroSense Files U.S. Patent Application for Traumatic Brain InjuryPRNewsWire · 5 days ago
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding MilestonesPRNewsWire · Oct 13, 2026
NeuroSense Provides Update on Nasdaq Listing CompliancePRNewsWire · Oct 2, 2026
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferencePRNewsWire · Sep 28, 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026PRNewsWire · Sep 25, 2026
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 10, 2026NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease.